Document is current
Any future updates will be listed below
-
Authors
Arbabi, Keon http://orcid.org/0000-0003-3219-8835
Newton, Dwight F.
Oh, Hyunjung
Davie, Melanie C.
Lewis, David A. http://orcid.org/0000-0002-3225-6778
Wainberg, Michael
Tripathy, Shreejoy J. http://orcid.org/0000-0002-1007-9061
Sibille, Etienne http://orcid.org/0000-0001-5832-6570
-
Funding
Funding for this research was provided by:
Ontario Graduate Scholarship Canadian Open Neuroscience Platform Initiative
CAMH Foundation Discovery Fund CAMH Foundation Krembil Startup Fund
Canadian Institute of Health Research Project Grant
- License Information
-
More Information
Article History
Received: 23 November 2023
Revised: 29 July 2024
Accepted: 19 August 2024
First Online: 5 September 2024
Competing interests
: ES is co-founder and CSO of Damona Pharmaceutical Inc., a biotech company developing GABAergic molecules for the treatment of cognitive dysfunctions in depression. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The authors confirm all relevant ethical guidelines have been followed, and necessary ethics committee approvals have been obtained from The University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents and Institutional Review Board for Biomedical Research. All necessary patient consent has been obtained and the appropriate institutional forms have been archived, and sample identifiers included were not known to anyone outside the research group so cannot be used to identify individuals.
